Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Chemotherapy in EGFR-TKI Resistant NSCLC (T790M Negative)
NCT03758677Phase 2Unknown
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by The First Hospital of Jilin University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03758677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758677.